PHILADELPHIA and VANCOUVER, British Columbia, Oct. 06, 2026 (GLOBE NEWSWIRE) — BriaCell Therapeutics Corp. (Nasdaq: ...
Independent DSMB reports no safety concerns to date and recommends continuing BriaCell’s pivotal Phase 3 ...
Now Enrolling Patients at Memorial Sloan Kettering Cancer Center (MSK) BriaCell Phase 3 trial featured ...
Cell-based immunotherapy program is designed to harness patients’ own immune systems Bria-MEL+ is a personalized, ...
FDA clearance of Investigational New Drug (IND) application enables BriaCell to initiate Phase 1/2a clinical ...
Final randomized Phase 2 Bria-IMT™ survival and quality of life data to be presented Biomarker ...
Bria-OTS+ platform provides early, potent and durable activation of innate and adaptive immunity in in-vitro ...
Phase 3 clinical data in heavily pretreated metastatic breast cancer patients with prior failed ADC, ...
PHILADELPHIA and VANCOUVER, British Columbia, March 31, 2026 (GLOBE NEWSWIRE) — BriaCell Therapeutics Corp. (Nasdaq: ...
PHILADELPHIA and VANCOUVER, British Columbia, March 18, 2026 (GLOBE NEWSWIRE) — BriaCell Therapeutics Corp. (Nasdaq: ...
Accessibility Tools
